Imfinzi made available on the NHS for Stage III NSCLC patients

Written by Jade Parker, Senior Editor

Imfinzi® (durvalumab) has become the first immunotherapy to demonstrate improvements in overall survival (OS) for Stage III non-small-cell lung cancer (NSCLC) patients. This breakthrough cancer treatment will now be available as a treatment option for patients in England via the Cancer Drugs Fund (CDF), subject to eligibility criteria being met. This decision follows a positive recommendation from the National Institute for Health and Care Excellence (NICE). “The availability of durvalumab is a watershed moment for lung cancer in England as it will change how we treat patients with Stage III disease,” commented Corinne Faivre-Finn from the University of Manchester (UK)...

To view this content, please register now for access

It's completely free